What is the role of hybrid capture-based NGS for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Where can NGS offer actionable insights and specific treatment roadmaps?

What is the role of hybrid capture-based NGS for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Where can NGS offer actionable insights and specific treatment roadmaps?

What is the role of hybrid capture-based NGS — full exome sequencing — for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Can you cite some specific patient examples where NGS can offer actionable insights and specific treatment roadmaps?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong